UBS AM
IGMS

UBS AM’s IGM Biosciences IGMS Stock Holding History

UBS AM’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,164
Closed -$1.34K – 2668
2025
Q1 		$1.34K Buy
+1,164
New +$2.17K ﹤0.01% 2635
2023
Q4 		– Sell
-11,145
Closed -$93.1K – 2567
2023
Q3 		$93.1K Sell
11,145
-473,882
-98% -$4.02M ﹤0.01% 2568
2023
Q2 		$6.66M Hold
485,027
– – ﹤0.01% 1113
2023
Q1 		$6.66M Buy
485,027
+328
+0.1% +$6.78K ﹤0.01% 1113
2022
Q4 		$8.24M Sell
484,699
-39,612
-8% -$792K ﹤0.01% 1011
2022
Q3 		$11.9M Sell
524,311
-12,098
-2% -$244K 0.01% 900
2022
Q2 		$9.67M Sell
536,409
-24,302
-4% -$433K 0.01% 970
2022
Q1 		$15M Buy
560,711
+200,032
+55% +$3.72M 0.01% 930
2021
Q4 		$10.6M Buy
360,679
+44,712
+14% +$2.22M ﹤0.01% 1110
2021
Q3 		$20.8M Sell
315,967
-19,612
-6% -$1.5M 0.01% 852
2021
Q2 		$27.9M Buy
335,579
+83,647
+33% +$6.2M 0.01% 800
2021
Q1 		$19.3M Sell
251,932
-47,018
-16% -$4.28M 0.01% 871
2020
Q4 		$26.4M Buy
298,950
+193,331
+183% +$13.6M 0.01% 772
2020
Q3 		$7.8M Buy
105,619
+26,287
+33% +$1.56M ﹤0.01% 1011
2020
Q2 		$5.79M Buy
+79,332
New +$4.82M ﹤0.01% 1061

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS AM's IGMS Position: Q2 2025 in Review

UBS AM sold out of IGM Biosciences (IGMS) in Q2 2025, closing a stake of 1,164 shares — an estimated $1.34K sold.

UBS AM first reported a position in IGMS in Q2 2020 and held it in 15 quarters. The position peaked at $27.9M in Q2 2021. 66 funds tracked by Wall St. Rank hold IGMS as of Q2 2025.

  • UBS AM reported no remaining IGM Biosciences position as of Q2 2025 after selling out during the quarter.
  • UBS AM sold 1,164 IGM Biosciences shares in Q2 2025, an estimated $1.34K.
  • UBS AM first reported a position in IGM Biosciences in Q2 2020 and held it in 15 quarters.
  • UBS AM's IGM Biosciences position peaked at $27.9M in Q2 2021.
  • 66 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2025.

Based on UBS AM's 13F filing for Q2 2025, filed 14 Aug 2025.